The American Society of Clinical Oncology (ASCO) is governed by a volunteer Board of Directors (including four Board officers) elected by ASCO’s member oncologists. The Chief Executive Officer serves on the Board as well. Elected Board members are cancer physicians and clinical researchers who volunteer their time to ASCO. Board members are not paid for their service, although their institutions receive stipends to partially cover the time and administrative resources dedicated to ASCO.
ASCO’s financial and other disclosures are governed by its own Policy for Relationships With Companies, the Council of Medical Specialty Societies’ CMSS Code for Interactions with Companies, and the Accreditation Council for Continuing Medical Education Standards. Consistent with the CMSS Code (Article IV, Section 2.4), ASCO here discloses the financial and uncompensated relationships between the Board of Directors and companies with a commercial interest in the science or practice of oncology.
Please direct any questions to COI@asco.org.
View the disclosures for the ASCO Board of Directors as of September 2017.
Dr. Hudis is the CEO of the American Society of Clinical Oncology. Previously he served for nearly two decades as the Chief of the Breast Medicine Service and Attending Physician at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City where he was also a Professor of Medicine at the Weill Medical College of Cornell University. He was co-chair of the Breast Committee of the Alliance for Clinical Trials in Oncology (formerly Cancer and Leukemia Group), Chair of the Scientific Advisory Committee of the Breast Cancer Research Foundation, a former Associate Editor of the Journal of Clinical Oncology, and the President of ASCO during its 50th anniversary year, 2013-2014.
For almost 30 years Dr. Hudis worked to develop more effective treatment and prevention for breast cancer. His early work focused on translating the kinetic predictions of the Norton-Simon model into more effective dose-dense adjuvant chemotherapy programs. For the past decade he has studied the interplay of inflammation, obesity, and cancer and his group described low grade, chronic white adipose inflammation in most overweight and obese women. His group has made similar observations in other malignancies and risk groups and have used these insights to inform intervention studies and public policy initiatives at an international level.
Bruce E. Johnson, MD, FASCO, is Chief Clinical Research Officer and Institute Physician at the Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School. He is the Director of the Dana-Farber/Harvard Cancer Center (DF/HCC) Lung Cancer Program. He stepped down as the Director of the Lowe Center for Thoracic Oncology, a position he held beginning in 1998 through 2013.
An ASCO member since 1985, Dr. Johnson has served in numerous volunteer and leadership roles, including the Board of Directors (2008-2011), Chair of the Audit, Cancer Education, and Cancer Communications Committees, and on the Journal of Clinical Oncology Editorial Board, among other positions. In 2008, he was award the Translational Research Professorship from the Conquer Cancer Foundation of ASCO.
Dr. Johnson has been active on committees and study sections within the National Cancer Institute, including recent service on the Special Emphasis Panel to review SPOREs, the Clinical Oncology Study Section, and on the Thoracic Malignancy Steering Committee, among others. He has served on a number of external advisory boards, including the External Advisory Committee for The Cancer Genome Atlas. He is a member of the Scientific Advisory Board for The University of Texas MD Anderson Moon Shots Program, and is active in the American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC), as well as other professional organizations. He was awarded the IASLC Scientific Award in 2009. In 2010, he was one of the leaders of the team honored with the AACR Team Science Award. He was elected to the Association of American Physicians in 2015.
Dr. Johnson earned his undergraduate degree from Harvard University and his medical degree from the University of Minnesota. He completed his internship and residency in internal medicine at the University of Chicago Hospitals and Clinics. He concluded his training as a Clinical Associate at the National Cancer Institute.
Monica M. Bertagnolli, MD, FASCO, is chief of the division of Surgical Oncology at Dana-Farber/Brigham and Women’s Cancer Center, a professor of surgery at Harvard Medical School, and an associate surgeon at Brigham and Women’s Hospital and Dana-Farber Cancer Institute. She has worked at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital since 2000. She previously served as an associate surgeon at the Strang Cancer Prevention Center in New York from 1994-2007 and as an attending surgeon at New York Presbyterian Hospital–Cornell from 1994-1999.
Since joining ASCO in 1995, Dr. Bertagnolli has served on the Board of Directors (2007-2011), as well as on numerous committees, including the ASCP/CAP/AMP/ASCO Colorectal Cancer Guidelines Committee (co-chair 2011-present), the Cancer Prevention Committee (2001-2004 and 2007-2010), and the Planning Committee (2008-2011), among others.
In addition to her ASCO involvement, Dr. Bertagnolli currently serves as vice president of Coalition of Cancer Cooperative Groups, group chair of Alliance for Clinical Trials in Oncology, president of the Alliance for Clinical Trials in Oncology Foundation, and CEO of Alliance Foundation Trials, LLC. Since 2012 she has served on the on the National Academy of Medicine’s National Cancer Policy Forum. In 2011, she received the Partners Healthcare Partners in Excellence Award: Personalized Cancer Medicine Partnership Team, and in 2015, she received the CEO Roundtable on Cancer Charles H. Sanders Life Sciences Award.
Dr. Bertagnolli received her undergraduate degree from Princeton University and her medical degree from the University of Utah College of Medicine; she performed her residency at Brigham and Women’s Hospital.
Daniel F. Hayes, MD, FACP, FASCO, is a Professor of Internal Medicine, the Stuart B. Padnos Professor in Breast Cancer, and the Clinical Director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center. He is a breast cancer specialist.
An ASCO member since 1986, Dr. Hayes has served the Society in numerous volunteer capacities. In addition to serving as Immediate Past President, he is involved in several ASCO Expert Panels related to breast cancer, including the ASCO-College of American Pathologists Estrogen Receptor/Progesterone Receptor and the HER2 Testing Panels (Co-Chair), the Breast Cancer Consensus Panel, Use of Tumor Biomarkers in Advanced Breast Cancer and Early-Stage Breast Cancer Panels, and the Breast Cancer Guideline Advisory Group, among others. He served on the ASCO Board of Directors from 2011-2014, on the Conquer Cancer Foundation Grants Selection Committee, as Chair of the Scientific Program Committee, and on the Journal of Clinical Oncology Editorial Board. In 2007, he was presented with ASCO’s Gianni Bonadonna Breast Cancer Award and Lecture; in 2013, he was elected as a Fellow of ASCO (FASCO).
Dr. Hayes is past Chair of the Breast Cancer Intergroup of North America’s Correlative Sciences Committee and Chair of the Southwest Oncology Group’s Breast Cancer Translational Medicine Committee. He is a member of the Union for International Cancer Control (UICC) TNM Expert Advisory Panel on Breast Tumours and the Early Breast Cancer Clinical Trials Collaborative Group (the Oxford Overview) Executive Committee. He serves on the Susan G. Komen for the Cure Scientific Advisory Council as a Komen Scholar, in addition to several other past and current leadership roles.
Dr. Hayes completed his undergraduate degree and master’s degree in biochemistry at Indiana University and obtained his medical degree from Indiana University School of Medicine. He completed his internship and residency at Parkland Memorial Hospital/University of Texas Southwestern Medical School and a medical oncology fellowship at Harvard Medical School’s Dana-Farber Cancer Institute.
Craig R. Nichols, MD, FACP recently joined Intermountain Healthcare to direct the Precision Genomics Cancer Research Clinic. He had previously served as the Co-Director of the Testicular Cancer Multidisciplinary Clinic at Virginia Mason Medical Center in Seattle, where he was a co-primary investigator on the Northwest National Cancer Institute Community Oncology Research Program. Dr. Nichols is the Executive Officer of Cancer Control and Prevention Research for the Southwest Oncology Group (SWOG). His clinical expertise is in testicular cancer.
Since joining ASCO in 1986, Dr. Nichols has served the Society in numerous volunteer capacities. Currently he serves as Co-Chair of the Management of Testicular Cancer Committee and as a member of the Practice Guidelines Implementation Network.
In addition to his ASCO involvement, Dr. Nichols serves or has served on the Board of Directors of the Livestrong Foundation, Executive Committee and Board of Trustees of the Oregon chapter of the Leukemia-Lymphoma Society, and the Autologous Bone Marrow Transplantation and Genitourinary Testis Subcommittees for the Eastern Cooperative Oncology Group. He currently is one of nine international experts serving on the initial Movember testicular cancer biomarker project and is continuing to lead work with national and international groups to develop patient- and provider-centered guidelines for germ cell tumors. Dr. Nichols is a member of the Clinical Trials Advisory Panel for the Patient-Centered Outcomes Research Institute and Chair of the Monitoring Funded Clinical Trials Subcommittee.
Dr. Nichols received his undergraduate degree in computer science from the University of Oregon and his medical degree from the Oregon Health Sciences University; he performed his internship and residency at the Alton Ochsner Medical Foundation and his fellowships at the University of Miami and Indiana University.
Peter C. Adamson, MD, is Chair of the Children’s Oncology Group, President of the Children’s Oncology Group Foundation, and a Professor of Pediatrics and Pharmacology at The Children’s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania. He has been a faculty member at the University of Pennsylvania since 1999.
Since joining ASCO in 1992, Dr. Adamson has served on the Cancer Research Committee (2011-2014) and the Scientific Program Committee (2007-2010), and on the Editorial Board of the Journal of Clinical Oncology (2007-2010).
President Barack Obama recently appointed Dr. Adamson to the National Cancer Advisory Board. He has previously served on the American Association of Cancer Research Pediatric Steering Committee (2011-2015), the National Cancer Institute’s Experimental Therapeutics Program (NExT) Special Emphasis Panel (2012-2015), as the Chair of Children’s Oncology Group Developmental Therapeutics Program (2000-2008), on the National Cancer Institute’s Investigational Drug Steering Committee (2005-2012), and on the Department of Defense Neurofibromatosis Research Programmatic Review Committee (1999-2004).
Dr. Adamson received his undergraduate degree from Wesleyan University and his medical degree from Cornell University Medical College. He performed his residency at The Children’s Hospital of Philadelphia and his fellowship in the Pediatric Oncology Branch of the National Cancer Institute.
Charles D. Blanke, MD, FACP, FASCO, is a Professor of Medicine in the Division of Hematology and Medical Oncology at Oregon Health and Science University’s Knight Cancer Institute. His research interests have mostly involved targeted systemic agents, and he has been instrumental in the development of imatinib mesylate for use in patients with locally advanced and metastatic gastrointestinal stromal tumors.
In addition to serving on the ASCO Board of Directors, Dr. Blanke also serves on the Ethics and Finance Committees. An ASCO member since 1995, he has served on the Publications Committee, Career Development Committee, Cancer Prevention Committee, Journal of Clinical Oncology Editorial Board, and Best of ASCO Planning Committee, among others. He has also served as Chair of the Cancer Education Committee and Co-Chair of the Gastrointestinal Cancers Symposium Program Committee.
He is the current Chair of SWOG (formerly the Southwest Oncology Group), where he has served as Chair of the Gastrointestinal Committee. He serves as Chair of the Gastrointestinal Stromal Tumor (GIST) Task Force for the National Cancer Institute's Gastrointestinal Steering Committee.
Dr. Blanke received his undergraduate and medical degrees in the Honors Program in Medical Education at Northwestern University; he performed his internship and residency at Gundersen Medical Foundation and his fellowship at Indiana University. He served as Chief Resident and Chief Fellow at those institutions, respectively. He has served as Vice-President of Systemic Therapy at the British Columbia Cancer Agency, Chief of the Division of Medical Oncology at the University of British Columbia, and Head of Medical Oncology at Vancouver General Hospital.
Linda Bosserman, MD, FACP, FASCO, is an Assistant Clinical Professor and staff physician at City of Hope. In addition to serving on the ASCO Board of Directors, Dr. Bosserman currently serves on Clinical Practice Committee and the Practice Guidelines Implementation Network. An ASCO member since 1990, she has served on the Public Issues Committee, and Quality Care Symposium Planning Committee.
Dr. Bosserman has served as Chief Quality Officer and Chief Medical Officer for the Cancer Clinics of Excellence; Secretary and Board of Directors member of the Community Oncology Alliance; Chair of the Cancer Committee for the San Antonio Community Hospital; Director of the Stem Cell, Psycho-Social Oncology, and Comprehensive Breast Programs; then as Associate and Medical Director of the Robert and Beverly Lewis Family Cancer Care Center. She served on the Board of Directors for the California American Cancer Society and chaired their state-wide Breast Cancer Committee. She participated in the White House Physician Forum on Health Reform in 2009 and in many clinical research trials.
She received her undergraduate degree in biochemistry with highest honors from the University of California, Berkeley, and her medical degree from Stanford University. Dr. Bosserman performed her internship and residency at Stanford University Hospital and did her oncology fellowship at the Dana-Farber Cancer Institute, Harvard Medical School, and Brigham and Women’s Hospital. Before she joined Wilshire Oncology in 1990, where she led her group’s pioneering work on oncology medical home care until 2014, she was a Clinical Instructor of Medicine at Harvard University and Stanford University School of Medicine. She joined the City of Hope Foundation in 2014 to continue her work as a breast medical oncologist and oncology medical home leader.
Walter J. Curran, Jr., MD, FACR, is the Executive Director of the Winship Cancer Institute of Emory University, the Lawrence W. Davis Professor and Chair of Emory’s Department of Radiation Oncology, and the Associate Vice President for Cancer at the Woodruff Health Sciences Center. In addition to serving on the ASCO Board of Directors, Dr. Curran currently serves on the Membership and Finance Committees. His clinical and translational research has focuses on brain tumors and thoracic malignancies.
An ASCO member since 1988, Dr. Curran has served as a member of the Cancer.Net Editorial Board, the Conquer Cancer Foundation Advanced Clinical Research Award (ACRA) in Glioma Selection Subcommittee, and the Cancer Research Committee. He has served as a Specialty Editor of Clinical Cancer Advances and as a liaison to the Scientific Program Committee, among other activities. In 2007, he received the ASCO Distinguished Service Award for Scientific Leadership.
Dr. Curran is one of three founding principal investigators of NRG Oncology and Chair of the NRG Oncology Foundation Board, as well as the founder of the Radiation Therapy Oncology Group (RTOG) Foundation. He served as Group Chair and principal investigator of the RTOG since 1998 and previously served as the RTOG Deputy Group Chair and Brain Tumor Committee Chair. He is a member of the National Cancer Institute National Clinical Trials Network Working Group and is on a number of editorial boards. Dr. Curran led the development of a universally adopted stratification system for brain tumors, a randomized trial defining the standard of care for patients with locally advanced lung cancer, and a randomized trial defining a new standard of care for patients with brain metastases. He has served as a principal investigator of over 20 federal grants, including a P01, P30, and a number of U10 NCI awards.
Dr. Curran received his undergraduate degree from Dartmouth College and his medical degree from Medical College of Georgia; he completed his internship at Presbyterian-University of Pennsylvania and his residency at the Hospital of the University of Pennsylvania. He served as Professor and Chair of the Department of Radiation Oncology at Jefferson Medical College and held faculty appointments at the University of Pennsylvania and the Fox Chase Cancer Center.
Stephen B. Edge, MD, FACS, FASCO, is the Vice President for Healthcare Outcomes Policy and Professor of Oncology at the Roswell Park Cancer Institute.
Since joining ASCO in 1988, Dr. Edge has co-chaired the 2010 Breast Cancer Symposium and Guideline Panel for Postmastectomy Radiation. He is currently serving on the Cancer Prevention and Audit Committees, as well as the Editorial Boards of the Journal of Oncology Practice, the Journal of Clinical Oncology, and Cancer.Net. He has also served on the Health Services Research Committee, the inaugural Quality Care Symposium Planning Committee, and as the Health Services Research Track Leader for the ASCO Annual Meeting.
Dr. Edge serves as Immediate Past Chair of the Commission on Cancer, on the Cancer Support Community Policy Institute of the National Advisory Board. He was the Co-Chair of the Technical Advisory Panel for Quality Measure Development in Oncology for the National Committee on Quality Assurance, and is now on the Centers for Medicare & Medicaid Services’ Hospital Inpatient and Outpatient Process and Structural Measure Development and Maintenance Panel.
He received his undergraduate degree from Tufts University and his medical degree from Case Western Reserve University; he performed his internship and residency at University Hospitals of Cleveland. His fellowship was completed at the Surgery Branch of the National Cancer Institute.
Arti Hurria, MD, FASCO, is vice provost of clinical faculty, professor and director of the Center on Cancer and Aging, and co-lead of the Cancer Control and Population Sciences Program at City of Hope. Dr. Hurria has been a faculty member at City of Hope since 2006.
Since joining ASCO in 2001, Dr. Hurria has served on several ASCO committees. She is Leader of the ASCO Geriatric Oncology Special Interest Group, Chair of the Professional Development Committee, Chair-Elect of the Cancer Research Committee, Associate Editor of the Cancer.Net Editorial Board, and a member of the Journal of Clinical Oncology Editorial Board. She has served on the Special Awards Selection Committee, as a Track Leader of the Cancer Education Committee, Chair of the Lifelong Learning Subcommittee, and on the Task Force on ASCO Volunteer Groups. Dr. Hurria is also a previous participant in the Leadership Development Program and recipient of the Conquer Cancer Foundation of ASCO’s Young Investigator Award and Career Development Award.
In addition to her ASCO involvement, Dr. Hurria is Chair and Founder of the Cancer and Aging Research Group, Vice Co-Chair for the Alliance Cancer in the Elderly Committee, Past President of the International Society of Geriatric Oncology, and Past Chair of the National Comprehensive Cancer Network Older Adult Oncology Committee (2010-2016). She has received many awards and honors, including ASCO’s B. J. Kennedy Award for Scientific Excellence in Geriatric Oncology, the Paul B. Beeson Career Development Award in Aging (K23), and the Frederick Stenn Memorial Award for Humanism in Medicine.
She received her medical degree from Northwestern Medical School; she completed her internship at Beth Israel Medical Center, her residency at Beth Israel Deaconess Medical Center, and her fellowships in Geriatrics and Oncology at the Harvard Geriatrics Fellowship Program and Memorial Sloan Kettering Cancer Center, respectively.
Maha Hussain, MD, FACP, FASCO, is the Genevieve Teuton Professor of Oncology and Professor of Medicine in the Division of Hematology Oncology, Department of Medicine, and the Associate Director for Clinical Research and Co-Leader of the GU Oncology Program at the Robert H. Lurie Comprehensive Cancer Center of the Northwestern University Feinberg School of Medicine. She is a practicing oncologist and internationally renowned expert and clinical researcher in genitourinary oncology, particularly in bladder and prostate cancers, and a noted teacher/mentor.
Since joining ASCO in 1990, Dr. Hussain has served on numerous committees and boards, including the Scientific Program, Cancer Education, International Affairs, and Cancer Communications committees. In addition, she chaired the Genitourinary Cancers Symposium Steering Committee (2013-2014), the Genitourinary Cancers Symposium Program Committee (2010-2011), and the Cancer Education Committee (2008-2009). She was also the Associate Editor for Cancer.Net from 2013-2014. She currently serves on the Clinical Practice Guidelines Committee and the ASCO Board of Directors.
In addition to her ASCO involvement, Dr. Hussain has served in a variety of national scientific roles, including as Co-Chair of the Prostate Cancer Subcommittee/Genitourinary Cancer Committee of SWOG (1994-2012) and as a member (2009-2014) and Chair (2013-2014) of the Integration Panel of the U.S. Army Medical Research and Materiel Command Prostate Cancer Research Program. She was also a member (2004-2008) and Chair (2007-2008) of the U.S. Food and Drug Administration Oncology Drug Advisory Committee. She currently serves as an EAB member for several NCI-designated cancer centers.
Dr. Hussain has received many honors, including the University of Michigan Comprehensive Cancer Center Leadership Award (2007), the University of Michigan Medical School League of Research Excellence (2011), and the 2012 Clinical & Health Services Research Award. She was elected as a Fellow of ASCO in 2010. In 2015 she was named one of OncLive’s Giants of Cancer Care.
Dr. Hussain received her medical degree from Baghdad University College of Medicine and performed her residency and fellowship at Wayne State University.
Reshma Jagsi, MD, DPhil, is professor and deputy chair of the Department of Radiation Oncology at the University of Michigan, where she is residency program director, treats breast cancer, and conducts health services research.
An ASCO member since 2004, Dr. Jagsi currently serves on the CancerLinQ® Data Governance Oversight Committee and the Bisphosphonates in Breast Cancer and Breast Cancer Consensus Expert Panels. She is a past chair of the Ethics Committee (member 2014-2016; chair 2014-2015). She has served on the Scientific Program Committee (2010-2012), and the Journal of Clinical Oncology (JCO) Editorial Board (2013-2015). Dr. Jagsi participated in ASCO’s Leadership Development Program in 2011-2012 and served as an ASCO representative to the American Medical Association.
Dr. Jagsi leverages her research expertise to extend her ASCO service, having published in The New England Journal of Medicine, JAMA, and JCO on issues directly related to her ASCO committee and advocacy experiences. She has an active R01 grant from the National Cancer Institute to study the ethical implementation of CancerLinQ. She has also been active in ASCO’s efforts to promote gender equity (the subject of another R01-funded research program she leads), through its Women’s Networking Center.
Dr. Jagsi received her undergraduate and medical degrees from Harvard, and her doctorate in Social Policy from Oxford as a Marshall Scholar. She completed her residency at the Massachusetts General Hospital/Harvard Radiation Oncology Program (where she was chief resident), as well as a fellowship at the Harvard Center for Ethics.
David Khayat, MD, PhD, FASCO, is the Head of the Department of Medical Oncology at Pitié-Salpêtrière Hospital, in Paris, France. He previously served as President of the French National Cancer Institute from 2004-2006.
An ASCO member since 1987, Dr. Khayat has served on the Cancer Education Committee and Special Awards Selection Committees. He served as Chair of the International Affairs Committee and Associate Editor of the Journal of Clinical Oncology, among other activities.
He has served on several editorial boards, including Cancer and Journal of Internal Medicine. He organized and was the first president of the French Federation of Medical Oncologists (FFOM) and received the National Order of Merit, the Legion of Honor, and the Academic Palms.
Dr. Khayat received his medical degree from the Pierre and Marie Curie University in Paris, where he completed his doctorate in tumor immunology and was Chief Clinical Assistant for the Department of Medical Oncology. He has taught at The University of Texas MD Anderson Cancer Center, Pierre and Marie Curie University in France, and Sino-French Institute of Onco-Hematology in China. He has been a visiting professor at the Mount Sinai School of Medicine.
Michael P. Kosty, MD, FACP, FASCO, is a member of the Scripps Green Cancer Center where he has practiced hematology and medical oncology since 1989. He has served as the director of Scripps Green Cancer Center in La Jolla, California, since 2008, director of Graduate Medical Education at Scripps Clinic/Scripps Green Hospital since 2002, and as director of the Hematology/Oncology Fellow Training Program at Scripps Clinic/Scripps Green Hospital since 1997. Since 1990, he has served at Scripps Green Cancer Center as head of the Thoracic Oncology Service, and as a member of the Genitourinary Oncology Service, Dermatologic Oncology Service, and the Clinical Research Advisory Committee.
Since joining ASCO in 1986, Dr. Kosty has served as the chair of the Continuing Medical Education Subcommittee (2013-2014), chair of the Oncology Training Program Subcommittee (2009-2010), chair of the Workforce Advisory Group (2015-2016), and is currently the chair-elect of the Professional Development Committee. In addition, he also served as a member of the Test Materials Development Committee and is ASCO co-chair of the European Society of Medical Oncology–ASCO Global Curriculum Workgroup. In recognition of his years of service to ASCO, Dr. Kosty received the distinction of Fellow of ASCO (FASCO) in 2014.
Dr. Kosty served as an investigator for the Southwest Oncology Group from 1999 to 2007 and as an investigator for the Cancer and Leukemia Group B from 1986 to 1999. Dr. Kosty dedicated many years to service in the military, as a general medical officer on the USS Belleau Wood (LHA-3; 1980-1981), as an attending physician and assistant head in the Division of Hematology/Oncology at the Naval Hospital (1986-1989), and as a member of the U.S. Naval Reserve (1989-1999).
Dr. Kosty received his undergraduate and master’s degrees from the University of California, Berkeley. He received his medical degree from George Washington University; he performed his internship, residency, and fellowship at Naval Hospital, San Diego. He was a visiting fellow at the Dana-Farber Cancer Institute at Harvard Medical School and a research fellow at the Scripps Clinic and Research Foundation.
J. Chris Nunnink, MD, FASCO, is an Attending Physician in Medical Oncology at the University of Vermont Medical Center (UVMMC ) and an Associate Professor at the Vermont Cancer Center and the College of Medicine at the University of Vermont, where he is developing a network for oncology care in rural upstate New York and Vermont. Before transitioning to UVMMC, he started a large private practice, the Vermont Center for Cancer Medicine, and ran this successful practice for 27 years.
Since joining ASCO in 1986, Dr. Nunnink currently serves on the Clinical Practice Committee. He has served on the State Affiliate Council and was the ASCO advisor to the Relative Value Scale Update Committee of the American Medical Association (AMA). Dr. Nunnink was elected as a Fellow of ASCO (FASCO) in 2011. He has served as an ASCO delegate to the AMA since 2010.
Dr. Nunnink is a member of the National Surgical Adjuvant Breast and Bowel Project, Cancer and Leukemia Group B/Alliance, and Cancer Committee at FAHC. He served as a Trustee for the Fanny Allen Hospital from 1994 to 1996 (when it merged with the Medical Center Hospital of Vermont to form UVMMC), President of the Northern New England Clinical Oncology Society in 2001 and 2007, and Vermont delegate to the AMA from 2007-2010.
Dr. Nunnink received his undergraduate degree from Indiana University and his medical degree from the College of Medicine at the University of Vermont; he performed his internship and residency at the Medical Center Hospital of Vermont and his fellowship at the Wisconsin Clinical Cancer Center.
Dr. Roberts is a Managing Member and portfolio manager at Farallon Capital Management, LLC. Prior to joining Farallon, Dr. Roberts was an attending oncologist at Massachusetts General Hospital, an Instructor of Medicine at the Harvard Medical School, and a Visiting Scientist at Massachusetts Institute of Technology. Dr. Roberts obtained two baccalaureate degrees (Summa Cum Laude) from the University of Pennsylvania, including a Bachelors of Science from the Wharton School of Business (Phi Beta Kappa junior year). He obtained his medical degree from Harvard Medical School. Dr. Roberts performed his internal medicine training at the Massachusetts General Hospital and his medical oncology training through the Dana-Farber/Partners Cancer Care Oncology Fellowship Program. Dr. Roberts has been an ASCO member since 2003.
Eric J. Small, MD, FASCO, is the deputy director of the UCSF Helen Diller Family Comprehensive Cancer Center, chief of the Division of Hematology and Oncology in the Department of Medicine at the University of California, San Francisco, and professor in residence in the Department of Medicine and Department of Urology. Dr. Small has worked at the University of California, San Francisco since 1988.
Since joining ASCO in 1992, Dr. Small has served as an associate editor for the Journal of Clinical Oncology (2008-2013), chaired the Molecular Markers Scientific Committee (2008-2009), chaired the Scientific Program Committee (2003-2004), served as the inaugural chair of the Prostate Cancer Symposium Steering Committee, and served as chair of the Prostate Cancer Symposium Program Committee (2004-2005). Dr. Small has chaired the grant writing workshop at the ASCO Annual Meeting. Dr. Small also served on the Nominating Committee (2007-2010) and the Conquer Cancer Foundation Grands Selection Committee (2009-2012), among other commitments. Dr. Small was named a Fellow of ASCO (FASCO) in 2015.
In addition to his ASCO involvement, Dr. Small is a member of the National Cancer Institute Initial Review Group Subcommittee A (Parent Committee for Cancer Centers, 2010-present), a member of the National Cancer Center Network Treatment Guidelines Panel (1999-present), and leads a 40-member Stand Up to Cancer Dream Team. Dr. Small served as chair of the CALGB (Alliance) Genitourinary Committee for 14 years, and in 2011, was awarded the Richard L. Schilsky CALGB Award.
Dr. Small received his undergraduate degree from Stanford University and his medical degree from Case Western Reserve University School of Medicine. He performed his internship and residency at Beth Israel Hospital (Boston), and completed his fellowship at the University of California, San Francisco.
Jaap Verweij, MD, PhD, FASCO, is a medical oncologist and currently Dean of the Faculty of Medicine at Erasmus University and Vice-Chair of the Board of Directors at Erasmus Medical Center. Dr. Verweij has been a faculty member of Erasmus University Medical Center since 1984.
Since joining ASCO in 1986, Dr. Verweij has served as Associate Editor of the Journal of Clinical Oncology and a member of the Scientific Program Committee, Conquer Cancer Foundation Grants Selection Committee, Multidisciplinary Cancer Management Committee, and Cancer Education Committee.
In addition to his ASCO involvement, Dr. Verweij currently serves as Vice-Chair of the Supervisory Board of the Dutch Cancer Foundation, a member of the Scientific Advisory Board for Aarhus University, a member of The Royal Netherlands Academy of Arts and Sciences, and a member of the Supervisory Board of the Erasmus University Holding. He previously served as Chair of the Supervisory Board of the Rotterdam Global Health Initiative, President of the Connective Tissue Oncology Society and for 22 years in various Board positions for the European Organisation for Research and Treatment of Cancer (EORTC), including as Vice-President, Chair of the EORTC Early Clinical Studies Group, Chair of the EORTC Soft Tissue and Bone Sarcoma Group, and Chair of the New Drug Advisory Committee. He has authored and co-authored more than 700 papers, mainly with a pharmacologic focus on new drug development.
He received his medical degree from the University of Utrecht, and completed his internship, residency, and fellowship at the Free University Hospital in Amsterdam.
Jedd D. Wolchok, MD, PhD, is Chief of the Melanoma and Immunotherapeutics Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSKCC). He is the Associate Director of the Ludwig Center for Cancer Immunotherapy at MSKCC, where he oversees immune monitoring and immunotherapy clinical trials. Dr. Wolchok is an Associate Professor in the Immunology and Microbial Pathogenesis Program at Weill Cornell Graduate School of Medical Sciences of Cornell University and an Associate Professor of Medicine at Weill Cornell Medical College. He is a Member of the Ludwig Institute for Cancer Research.
Dr. Wolchok joined ASCO in 1998 and has taken on numerous leadership roles, including Chair of the Scientific Program Committee and the Best of ASCO® Planning Committee. He has served on the Journal of Clinical Oncology Editorial Board, the Cancer Education Committee, and the Conquer Cancer Foundation Grants Selection Committee.
Dr. Wolchok’s professional achievements have been recognized with the Melanoma Research Foundation Humanitarian Award in 2010 and the Melanoma International Foundation’s Doctor of the Year Award in 2012, among other honors. He was named the Virginia and Daniel K. Ludwig Chair for Clinical Investigation in 2013. In 2014, he was recognized with the American Association for Cancer Research Richard and Hinda Rosenthal Memorial Award and the Giants of Cancer Care in Melanoma Award, as well as being elected to membership in the American Society for Clinical Investigation.
He received his undergraduate degree from Princeton University and his master’s, medical, and doctorate degrees from New York University. He completed his internship and residency at the New York University Medical Center/Bellevue Hospital and his fellowship at MSKCC, where he was named Chief Fellow in Medical Oncology-Hematology.